Lenvatinib is an oral multi-kinase inhibitor (MKI) that suppresses tumor cell proliferation and tumor angiogenesis via the inhibition of VEGFR1-3, FGFR1-4, PDGFR alpha, RET protein, and c-Kit protein (Figure 2B) [96]. Here, PDGFRA is linked to neoplasm.